ÂÜÀòÂÒÂ×

Marc de Somer MD ScD MPH MSc MBA has held various leadership roles in the pharmaceutical and biotech industry since 2006. Marc began their career at Cervelo Pharmaceuticals, Inc. as Chief Medical Officer & Executive Vice President, R&D in 2006. In 2008, they became a Strategic Advisor to the CEO at Adagio Pharmaceuticals, which later merged with Cynapsus Therapeutics. In 2010, they joined Alkermes as Vice President of Clinical Development & Medical Affairs. From 2014 to 2017, they worked at PPD as VP Global Product Development Neuroscience, where they developed innovative clinical trial and biostatistical methodology using modeling and simulation to inform decisions and optimize study design, execution and evaluation. In 2018, they began working as Chief Medical Officer for CMO-level Clinical-Medical-Quant Consulting. In 2019, they became Chief Medical Officer for Prilenia. In 2020, they joined Relmada Therapeutics, Inc. as SVP Clinical Development and Safety. In 2022, they began working as Chief Medical Officer for MAXONA Pharmaceuticals and as Clinical Development Lead Advisor to Corporate Leadership for multiple start-up biotechs.

Marc de Somer obtained their MD from Vrije Universiteit Brussel in 1973-1980. Marc then obtained their MPH in Public Health, Epidemiology, and Biostatistics from Université libre de Bruxelles in 1977-1982. Marc then obtained their ScD in Tropical Medicine / Infectious Diseases from Prins Leopold Instituut voor Tropische Geneeskunde in 1980-1982. Marc then obtained their MSc in Biostatistics from the Joint Biostatistics MSc program Harvard School of Public Health/Imperial College/Leuven/Diepenbeek in 1988-1989. Marc then obtained their MSc in Swiss FMH Pharmaceutical Medicine Specialty from the University of Basel in 1992-1993. Finally, they obtained their MBA in Business administration from Columbia Business School in 1996-1998.